Annual report pursuant to Section 13 and 15(d)

Licensing Arrangements (Details Narrative)

v3.23.1
Licensing Arrangements (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
Apr. 26, 2022
Apr. 26, 2022
Dec. 31, 2022
Dec. 31, 2021
Offsetting Assets [Line Items]        
Research and Development Expense     $ 4,770,834 $ 3,163,485
Sublicense And License Agreements [Member]        
Offsetting Assets [Line Items]        
Number of consideration shares issued 875,000      
Asset Acquisition, Consideration Transferred $ 1,300,000      
Payments to Acquire Productive Assets     500,000  
Number of shares purchase of asset, value $ 800,000      
Research and Development Expense     1,300,000  
Patent Assignment [Member]        
Offsetting Assets [Line Items]        
Research and Development Expense     500,000  
D Nase Technology [Member]        
Offsetting Assets [Line Items]        
Consulting, transaction and development costs     $ 600,000  
Sublicense Agreement Shares [Member] | CLS [Member]        
Offsetting Assets [Line Items]        
Number of consideration shares issued   375,000    
Sublicense And License Agreements [Member] | CLS [Member]        
Offsetting Assets [Line Items]        
Number of consideration shares issued   500,000    
Payments for Other Fees   $ 500,000